Download original image
Fig. 3. The IP3 receptor antagonist 2-APB and the ryanodine receptor antagonist TMB-8 inhibits 0.1 mM [Mg2+]o-induced [Ca2+]i spikes. (A) 0.1 mM [Mg2+]o-induced synchronized and repetitive [Ca2+]i spikes within 30 sec at day 11.5. (B) 2-APB (30 µM) inhibits 0.1 mM [Mg2+]o-induced [Ca2+]i spikes. (C) TMB-8 (10 µM) inhibited 0.1 mM [Mg2+]o-induced [Ca2+]i spikes. (D, E) Graph summarizing the frequency (D) and the area under the curve (E) of 0.1 mM [Mg2+]o-induced [Ca2+]i spikes in non-treated (control, n = 21), 2-APB-treated (n = 21), and TMB-8-treated (n = 21) cells. Relative spike frequencies or area under curves (2nd /1st: drug or non-treatment; 3rd / 1st: 0.1 mM [Mg2+]o wash) were shown as a ratio of an initial [Ca2+]i spike frequency and area under curves for 1st 0.1 mM [Mg2+]o treatment. Data are expressed as means ± SEM. IP3, inositol-1,4,5-trisphosphate; 2-APB, 2-aminoethoxydiphenyl borate; TMB-8, 8-(diethylamino)octyl 3,4,5-trimethoxybenzoate. **p < 0.01 relative to respective control (ANOVA with Bonferroni test), *p < 0.05 relative to respective control (ANOVA with Bonferroni test), ++p < 0.01 relative to respective control and TMB-8 (ANOVA with Bonferroni test).
Korean J Physiol Pharmacol 2022;26:531-540
© Korean J Physiol Pharmacol